Adalimumab-induced IgA nephropathy

Singh, Aneesha Kaur Bhagat; Jeyaruban, Andrew; Wilson, Gregory J.; Ranganathan, Dwarakanathan

doi:10.1136/bcr-2018-226442

Cited by 19 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar findings were reported for TNF-α, where higher serum levels proved to be a potential biomarker for evaluating disease severity as they were linked with proteinuria and renal function decline [ 75 ]. Interestingly, however, TNF-α inhibitors have been identified as a potential cause for IgAN, which was reported for use of adalimumab , but not for infliximab [ 76 ]. Nonetheless, their use in patients with rheumatoid arthritis from the KOBIO registry did not influence any change in renal function [ 77 ].…”

Section: Cytokinesmentioning

confidence: 99%

Review on Inflammation Markers in Chronic Kidney Disease

et al. 2021

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is one of the major health problems of the modern age. It represents an important public health challenge with an ever-lasting rising prevalence, which reached almost 700 million by the year 2017. Therefore, it is very important to identify patients at risk for CKD development and discover risk factors that cause the progression of the disease. Several studies have tackled this conundrum in recent years, novel markers have been identified, and new insights into the pathogenesis of CKD have been gained. This review summarizes the evidence on markers of inflammation and their role in the development and progression of CKD. It will focus primarily on cytokines, chemokines, and cell adhesion molecules. Nevertheless, further large, multicenter studies are needed to establish the role of these markers and confirm possible treatment options in everyday clinical practice.

show abstract

Section: Cytokinesmentioning

confidence: 99%

Review on Inflammation Markers in Chronic Kidney Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a case, a patient with CD who developed adalimumab-induced IgAN recovered after switching to infliximab. 16 However, our series demonstrates a possible class effect. With the advent of novel biologics with alternative mechanisms of action, it may be preferable to choose an alternative class agent.…”

Section: Discussionmentioning

confidence: 52%

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Tumor necrosis factor-α (TNF-α)-inhibiting agents are a standard therapy for moderate-to-severe inflammatory bowel disease (IBD). IgA nephropathy in the setting of prolonged exposure to TNF-α inhibitors is a rare, clinically significant adverse event often overlooked by gastroenterologists but well documented in the rheumatologic literature. We present a case series of 3 patients with IBD on TNF-α inhibitors who developed biopsy-proven IgA nephropathy. Clinicians prescribing TNF-α inhibitors to patients with IBD need to be aware of this potential side effect. Therapies with alternative mechanisms of action should instead be considered.

show abstract

“…It was suggested that induction of IgAN is not a class effect of TNFα antagonists as infliximab may even reduce proteinuria and induce remission of IgAN [ 34 ] and has been used successfully as a replacement drug in a patient with CD in whom adalimumab has caused IgAN [ 7 ]. Recently published case reports reported patients in whom infliximab triggered IgAN [ 28 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

“…In most cases, the disease is idiopathic, but it can be associated with other conditions, such as Crohn's disease [ 5 ]. There are some reports that tumor necrosis factor alpha (TNFα) could be the inducer of IgAN [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

IgA Nephropathy in a Patient Treated with Adalimumab

Mertelj

Smrekar

Kojc

et al. 2021

Case Rep Nephrol Dial

View full text Add to dashboard Cite

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by IgA deposits in the glomerular mesangium. It has a progressive nature and can eventually lead to end-stage kidney failure. It can occur as a potential side effect of treatment with tumor necrosis factor alpha antagonist that has been used for numerous chronic inflammatory conditions, such as Crohn’s disease. In this study, the case of a 33-year-old man with renal dysfunction, nephrotic proteinuria, and erythrocyturia is described. He had had a history of Crohn’s disease for 8 years and had been treated with adalimumab for the past 7 years. The diagnosis of IgAN was confirmed by kidney biopsy. After discontinuance of adalimumab and the induction of corticosteroid therapy, he made a remarkable recovery. Four years after the first presentation of IgAN and discontinuation of adalimumab, his renal function was normal with no proteinuria and only mild erythrocyturia.

show abstract

Adalimumab-induced IgA nephropathy

Cited by 19 publications

References 15 publications

Review on Inflammation Markers in Chronic Kidney Disease

Review on Inflammation Markers in Chronic Kidney Disease

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease

IgA Nephropathy in a Patient Treated with Adalimumab

Contact Info

Product

Resources

About